CARDIOVASCULAR DISEASES IN CANCER PATIENTS
Keywords:
chemotherapy, cardiotoxicity, myocardial dysfunction and heart failure, arrhythmia, ischemia, early detection, follow-upAbstract
The development of cardiovascular diseases (CVD) is one of the most common side effects in the treatment of patients with oncopathology as a result of the toxic effect of antitumor treatment on the function and structure of the heart or as a result of accelerated development of CVD with already existing cardiovascular risk factors. The article describes in detail the various stages of monitoring the functioning of the cardiovascular system and decision-making before, during and after the end of anticancer treatment, based on the recommendations of the EOC for the treatment of oncological diseases and cardiovascular toxicity in 2016.
References
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines / The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) // Eur. Heart. J. – 2016. – Vol. 21, № 37 (36). – Р. 2768–2801.
E. T. Yeh, C. L. Bickford. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management / // J. Am. Coll. Cardiol. – 2009. – № 53. – Р. 2231–2247.
J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent [et al.]Cancer incidence and mortality patterns in Europe:estimates for 40 countries in 2012. // Eur. J. Cancer.2013. –№ 49. – Р. 1374–1403.
K.C. Oeffinger, A. C. Mertens, C. A. Sklar [et al.]Cancer Survivor Study. Chronic health conditions in adult survivors of childhood cancer / // N. Engl. J. Med. – 2006. – № 355. – 1572–1582.
Limat, E. Daguindau, J. Y. Cahn [et al.]. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin’s lymphoma / S// J. Clin. Pharm. Ther. – 2014. – № 39. – Р. 168–174.
M.G. Khouri, P. S. Douglas, J. R. Mackey [et al.]Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues / // Circulation 2012. – № 126. – Р. 2749–2763.
M.S. Ewer, S. M. Ewer Ewer M. S. Cardiotoxicity of anticancer treatments / // Nat Rev Cardiol. – 2015. – № 12. – Р. 620.
P.S. Hall, L. C. Harshman, S. Srinivas, R. M. Witteles. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients / // JACC Heart Fail. – 2013. – № 1. – Р. 72–78.
R. Siegel, C. DeSantis, K. Virgo [et al.]Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. –2012. – № 62. – Р. 220–241.
S.M. Swain, F. S. Whaley, M. S. Ewer. Swain S. M. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials / // Cancer. – 2003. – № 97. – Р. 2869–2879.
